-
Cell Resource Library!
Time of Update: 2021-10-02
A meta-analysis of genome-wide association studies was performed and 100 independently associated risk variants among 11 osteoarthritis phenotypes were identified, 52 of which were not previously associated with the disease .
-
BTK Inhibitors: Progress in the Development of 10 Autoimmune Diseases
Time of Update: 2021-10-02
5. Multiple sclerosis (MS) Compared with other autoimmune diseases and healthy controls, BCR stimulated multiple sclerosis B cells and did not show an increase in BTK protein expression or pBTK levels .
-
[JAMA Sub-Journal] A large-scale study of 39,000 doses of vaccinations based on the mRNA new crown vaccine tells you the answer: Are there many allergic reactions to the new crown vaccine?
Time of Update: 2021-10-01
Recently, a study published in the journal "JAMA Network Open" showed that 22 potential allergic reactions to 38895 doses of mRNA-based COVID-19 vaccine were analyzed, and it was found that they may be sensitive to PEG before vaccination, and the mRNA itself did not cause allergies.
-
[Genome Medicine] So far the first to use gut microbial data in the prognosis study of rheumatoid arthritis, which is expected to become the key to future treatment!
Time of Update: 2021-10-01
The results of this study indicate that changing the gut microbiota to improve clinical efficacy is expected to become a future treatment for RA .
-
Detailed explanation: The latest review of the efficacy and safety of rituximab in the treatment of ANCA-related vasculitis
Time of Update: 2021-10-01
Studies have shown that in patients with new-onset and relapsed GPA/MPA, the efficacy of RTX to induce remission is not inferior to cyclophosphamide .
The RAVE study included 197 patients with GPA/MPA and compared the efficacy of 375 mg/m2/w RTX and oral cyclophosphamide (2 mg/kg/d) for 4 weeks to induce remission .
-
STTT Central South University Lu Qianjin and other teams found potential therapeutic targets for systemic lupus erythematosus
Time of Update: 2021-10-01
In conclusion, the results of this study show that AIM2 is highly expressed in B cells of patients with lupus and promotes B cell differentiation by regulating the Bcl-6-Blimp-1 axis, providing a new target for SLE treatment .
-
This index is less than 150ng/ml, ANCA-related vasculitis can be relieved continuously!
Time of Update: 2021-10-01
Figure 4 TIMP-1 potential to monitor disease activity TIMP-1 <150ng/ml, AAV long-term maintenance remission Professor Jun Ishizaki collected follow-up data at 3, 6, 12 and 18 months of treatment and at the time of relapse, including clinical manifestations and experiments Laboratory data, etc.
-
The latest progress in the treatment of psoriatic arthritis, don't hurry up and collect it!
Time of Update: 2021-10-01
Professor Philip Mease concluded that there have been many head-to-head trials on treatment, including traditional or conventional disease-improving anti-rheumatic drugs (DMARDs), biological agents such as TNFi, IL-17 inhibitors (IL-17i), and IL- 12/23 inhibitors (IL-12/23i), T cell regulators and new targeted synthetic DMARDs include phosphodiesterase 4 inhibitors and JAK inhibitors [1] .
-
"Yaodu Yaowen" Abrocitinib was first approved for the treatment of atopic dermatitis, and K drug was approved for the first-line treatment of esophageal cancer...
Time of Update: 2021-10-01
On September 9, 2021, Pfizer announced that the Medicines and Health Products Administration (MHRA) of the United Kingdom has approved Abrocitinib as an oral JAK1 inhibitor for adults and adolescents over 12 years of age who are suitable for systemic treatment with moderate to severe atopic dermatitis (AD ), the approved recommended doses are 100 mg and 200 mg once a day .
-
Decoding the rheumatism live room ②Innovation of systematic evaluation guidelines, biological agents and traditional treatment methods complement each other
Time of Update: 2021-10-01
Systemic Lupus Erythematosus Disease Activity Score (SLEDAI) has many clinical applications, mainly to assess the disease activity of patients, but the assessment of organ damage is not thorough [4] .
-
Thrombocytopenia?
Time of Update: 2021-10-01
Experts comment that thrombocytopenia is one of the common clinical manifestations of rheumatic immune diseases, which can lead to an increased risk of bleeding in patients.
-
In-depth interpretation of the 2021 version of the ACR guidelines to grasp the new trend of RA treatment
Time of Update: 2021-10-01
In terms of specific treatment recommendations, the update of the new version of the guidelines mainly includes the following points: The 1.
2015 version of the guidelines points out that for RA patients with low/medium/high disease activity, it is recommended to use traditional synthetic disease-improving anti-rheumatic drugs (csDMARD) monotherapy.
-
Ten latest developments in systemic vasculitis in the Asia-Pacific region!
Time of Update: 2021-10-01
It is recommended that certain GCA patients (including refractory or relapsed diseases, increased risk of glucocorticoid-related adverse events or complications) use tocilizumab for adjuvant therapy, and methotrexate can be used as a substitute .
-
Is it so difficult to diagnose Sjogren's syndrome?
Time of Update: 2021-10-01
*Only for medical professionals to read for reference. Non-invasive and convenient, can ultrasound carry the banner of pSS diagnosis? Sjogren’s syndrome (SS) is a chronic multi-system involved autoi
-
Sci Adv Tang Li's team uses chemical methods to achieve specific activation of immunomodulatory proteins in tumor tissues
Time of Update: 2021-10-01
When Sw-IM enters the tumor tissue with the blood circulation, the specific stimulation of the tumor microenvironment can effectively cut off the environmentally responsive chemical bond in the connection structure to remove the shielded polymer, thereby specifically "turning on" in the tumor tissue "The biological activity of immunomodulatory proteins .
-
List more than 10 kinds of new drugs, the new hope of osteoarthritis patients!
Time of Update: 2021-10-01
The results of the current phase II clinical trial (FORWARD) of recombinant human fibroblast growth factor 18 (Sprifermin) show that compared with the placebo group, Sprifermin can significantly improve cartilage thickness, and 100μg injection every 6 months in the joint cavity has the best effect [1].
-
What are the characteristics of RA patients who can achieve "deep clinical remission"?
Time of Update: 2021-10-01
This multi-center, large-sample RA remission rate study in the Asia-Pacific region included 2010 RA patients in 17 centers in 11 countries and passed different remission standards (including DAS28-CRP, DAS28-ESR, CDAI, SDAI, Boolean, and CliDR).
-
[Science] Vitamin A can be used to treat digestive system diseases, did you know?
Time of Update: 2021-10-01
"Now that we have a better understanding of this important aspect of immune function, we may eventually be able to manipulate how vitamin A is delivered to the immune system for disease treatment or prevention," Howard Hughes Medical Institute (Howard Hughes Medical Said Lora Hooper, a researcher at the University of Texas Southwestern Medical Center and Professor of Immunology .
-
China Biological Lancet publishes data on the use of Sinopharm's new crown vaccine among 3-17 year-olds
Time of Update: 2021-10-01
In order to further evaluate the safety and immunogenicity of the new coronavirus inactivated vaccine used in people aged 3-17 years, the Beijing Institute of Biological Products of Sinopharm Group launched an evaluation of the new coronavirus inactivated vaccine (Vero cell) in 3- Results of a randomized, double-blind, placebo-controlled phase I/II clinical trial on the safety and immunogenicity of vaccination in a 17-year-old healthy population .
-
Decoding the rheumatism live broadcast room ①Improve the standardization of rheumatism diagnosis and treatment to benefit more rheumatism patients
Time of Update: 2021-10-01
The clinical application of hormones, immunosuppressants, and biologically targeted drugs can better control lupus, reduce the time and dose of hormone use, so that the patient's disease can be stabilized as soon as possible, while also avoiding long-term organ damage .
